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Abstract
Background: Animal studies have shown that diet-induced hypercholesterolemia (HC) increases 
amyloid-β (Aβ) accumulation and accelerates Alzheimer’s disease (AD) pathology. However, the 
association of HC with AD in human studies has not been consistently established.
Objective: We aimed to investigate the relationship between HC and risk of AD neuropathology 
in a large national sample with autopsies.
Methods: This study used neuropathological and clinical data from 3,508 subjects from the 
National Alzheimer’s Coordinating Center (NACC) who underwent autopsies from 2005 to 2017. 
Demographic and clinical characteristics, as well as neuropathological outcomes were compared 
between subjects with and without HC. Associations between HC and AD neuropathology were 
examined by multivariate ordinal logistic regressions adjusting for potential confounders.
Results: HC was not associated with any AD neuropathology in a model only adjusting for 
demographic variables. However, HC was significantly associated with higher CERAD neuritic 
and diffuse plaque burden, higher Braak stage, and more severe cerebral amyloid angiopathy when 
analyzed in a multivariate model controlling for comorbidities. Additional adjusting for 
cerebrovascular conditions did not diminish these associations. The association between HC and 
increased risk of neuritic plaques weakened but remained significant even after controlling for 
ApoE genotype.
Conclusion: This study suggested that HC was associated with increased severity of AD 
pathology, which could only be partially accounted for by ApoE genotype. The associations were 
not mediated by cerebrovascular conditions.
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INTRODUCTION
More than 25 million people lived with dementia worldwide, most of whom are suffering 
from Alzheimer’s disease (AD) [1]. The long duration of illness in a state of disability and 
dependence makes it a significant burden to public health and health care system [2]. 
Epidemiological studies have identified multiple modifiable risk and protective factors. 
Among them, vascular risk factors are most consistently reported, including hypertension 
[3], type II diabetes [4], and cerebrovascular disease (CVD) [5].
The hallmark pathological changes in AD patients’ brain tissue involve amyloid-β (Aβ) 
peptide deposition and tau hyperphosphorylation [6]. Aβ production and clearance are 
regulated in part by cholesterol pathway. The strongest common genetic risk factor, a variant 
of ApoE, is an apolipoprotein that plays an essential role in cholesterol metabolism. Altered 
cholesterol metabolism may induce a change in membrane properties, leading to an 
alteration in Aβ production [7]. Cholesterol oxidation products, oxysterols, are suggested to 
be the link between altered cholesterol metabolism in the brain and Aβ aggregation [8].
Animal studies have shown that diet-induced hypercholesterolemia (HC) increases Aβ 
accumulation and accelerates AD pathology in rabbit brains [9] and in a transgenic mouse 
model [10, 11]. The authors therefore proposed that dietary control could be used to modify 
the risk of AD. Two statins have shown a pleiotrophic effect to achieve cognitive 
improvement in transgenic AD mouse model, without affecting serum lipid levels [12]. 
However, the association of HC with AD in human studies has not been consistently 
established. Elevated serum total cholesterol in midlife [13] and in the elderly [14] is found 
to be associated with an increased risk of AD. However, a community-based cohort study 
[15] did not find an association between serum total cholesterol and subsequent incidence of 
AD. Furthermore, a recent meta-analysis on the association between serum cholesterol and 
dementia has identified significant gaps in the literature regarding HC and AD risk [16]. 
Some studies suggest that dyslipidemia increases the risk of plaque-type AD pathology, but 
not the densities of neurofibrillary tangles (NFT) [17, 18]. But other lines of evidence do not 
support this association [19, 20].
In this study, we use the National Alzheimer’s Coordinating Center (NACC) database to 
investigate the relationship between HC and AD neuropathologic outcomes, including 
neuritic plaques (NP), NFTs, diffuse plaques (DP), and cerebral amyloid angiopathy (CAA). 
We further examine whether vascular pathology was a mediator between HC and AD 
neuropathology.
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Data sources and study populations
The National Alzheimer’s Coordinating Center (NACC) database is the largest resource of 
standardized clinical and neuropathological data related to AD in the U.S. NACC collects 
data from approximately 32 past and present Alzheimer’s Disease Centers (ADCs) across 
the United States since the beginning of the program in 1984. Data collection was fully 
standardized across centers in 2005 with the development of the Uniform Data Set [21]. 
Data collected between September 2005 and February 2017 were used in this analysis.
We used the following demographic variables: age at death, race, sex, and education. Self-
or-caregiver-reported subject medical history was longitudinally collected from initial visit 
and each annual follow-up visit at ADCs. A series of medical conditions were dichotomized 
as present or absent and were controlled for as potential confounders, including HC, stroke, 
transient ischemic attack, diabetes, cardiovascular disease, and hyper-tension. History of 
cardiovascular disease was coded as present or absent, by combining 9 types of 
cardiovascular disease recorded in the UDS form, including heart attack/cardiac arrest, atrial 
fibrillation, angioplasty/endarterectomy/stent, cardiac bypass procedure, pacemaker and/or 
defibrillator, congestive heart failure, angina, heart valve replacement or repair, and other 
cardiovascular disease. Presence of any one or more of these was coded as positive 
cardiovascular disease. In addition, self or caregiver reported use of lipid lowering 
medication was collected from each visit. ApoE genotype was available for 87.5% of the 
subjects in our study and coded as number of ε4 alleles (0, 1, or 2).
Assessment of neuropathologic measures
Neuropathologic data were obtained from NACC’s standardized Neuropathology Form [21, 
22]. Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) stages of Aβ NP 
densities were recorded as none, sparse, moderate, or frequent [23]. Braak scores for 
neurofibrillary degeneration were used with stage 0 indicating no degeneration and stage VI 
indicating NFTs found throughout the neocortex [24]. CAA stage was classified as none, 
mild, moderate, and severe. AD neuropathologic change (ADNC) and Thal phase for 
amyloid plaques by immunohistochemistry were included in the Neuropathology Form after 
2014. These data were excluded from this study due to limited sample size.
To describe the severity of cerebrovascular conditions, we dichotomized 6 groups of 
neuropathology as present or absent, including large artery infarcts or lacunes (old/acute/
subacute), hemorrhages (old/acute/subacute), microinfarcts (old/acute/subacute), subcortical 
arteriosclerotic leukoencephalopathy, atherosclerosis of the Circle of Willis and 
Arteriolosclerosis [25]. Acute and old/subacute CVD neuropathology were evaluated 
separately in the most recent version of the Neuropathology Form, but together in older 
versions. We combined these categories in order to use all data available. Infarcts observed 
grossly and lacunes were grouped together according to the newest version. Subjects were 
scored 0–6 by the numbers of CVD neuropathology groups observed in the brain.
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Demographic, clinical, and neuropathologic characteristics were compared between subjects 
with or without HC using Pearson chi-square tests for unordered categorical variables, t-tests 
for continuous variables, and Wilcoxon-Mann-Whitney tests for ordinal variables.
We used proportional odds ordinal regression model with generalized estimating equations 
to account for ADC clustering to analyze the association between HC status and each of the 
five neuropathology outcomes, namely, CVD score, Braak stage, CERAD NP and DP 
density, and CAA severity. We created four separate models. In the first multivariable model, 
we only controlled for age at death, year of education, sex, and race. In the second model, 
we additionally controlled for relevant comorbidities including hypertension, cardiovascular 
disease, diabetes, history of stroke or transient ischemic attack, each as a separate variable. 
An indicator for ApoE ε4 carrier status was included in the third model, which was limited 
to the subjects that had ApoE ε4 information available. This model examined whether ApoE 
ε4 is a mediator in the relationship between HC and severity of AD neuropathology. Lastly, 
CVD score was included in the fourth model to investigate whether CVD is a mediator in 
the relationship between HC and pathology burden. Significance was defined as p value < 
0.05.
RESULTS
Total of 3,508 subjects were included in the analysis, who underwent brain autopsies and 
had non-missing Braak, CERAD, CAA, and CVD staging scores. Demographic and clinical 
characteristics are summarized and compared by subjects’ HC status in Table 1. There were 
no significant differences in age at death, race, and education levels between subjects with 
and without HC. There were more males in subjects with HC than those without. Subjects 
with a history of HC were more likely to carry one or more ApoE ε4 alleles and to have 
other medical conditions, such as cardiovascular disease, hypertension, diabetes, stroke, and 
transient ischemic attack.
In the unadjusted between-group comparisons subjects with HC had higher CERAD DP 
density scores and more severe CAA (Table 2) than those without HC. Subjects with HC did 
not differ significantly in CVD scores, CERAD NP score, or Braak score for NFTs from 
those without HC (Table 2).
Table 3 summarizes the results of our multivariate models. In Model 1 where we adjusted for 
age at death, sex, race, and education only, HC was not significantly associated with any of 
the neuropathologic outcomes. There were significant associations between HC and all AD 
neuropathology outcomes after additionally adjusting for comorbidities (Model 2). 
Specifically, having a history of HC was associated with a 21%, 26%, 32%, and 26% higher 
odds of having higher Braak (OR = 1.21 [95% CI: 1.04–1.43]), higher CERAD NP density 
score (OR = 1.26 [1.08–1.47]), higher CERAD DP density score (OR = 1.32 [1.06–1.64]), 
and more severe CAA (OR = 1.26 [1.08–1.47]), respectively (Model 2). HC was also 
associated with lower CVD score with borderline significance (p value = 0.0436) (Model 2).
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We investigated whether the association between HC and AD neuropathology was mediated 
by ApoE ε4 genotype or cerebrovascular conditions (Models 3 and 4, respectively). We 
found that ApoE ε4 genotype was significantly associated with all neuropathologic 
outcomes. After controlling for ApoE ε4 allele carrier status, the associations between HC, 
CVD, Braak stage, CERAD DP, and CAA became nonsignificant. The association between 
HC and CERAD NP was reduced, but remained significant. The associations between HC 
and all four pathologic indices, Braak stage, CERAD NP and DP density. and CAA, all 
remained significant after adjusting for CVD score in the model (Model 4). We further 
evaluated the effect of lipid lowering medication on the connection between HC and AD 
pathology. Lipid lowering medication itself was not significantly associated with any 
pathological outcomes evaluated. The associations between HC and four AD pathologic 
indices all remained significant after adjusting for lipid lowering medication use (Model 5).
We found that ApoE ε4 genotype was significantly associated with all neuropathologic 
outcomes. We further examined the association between ApoE ε4 genotype and NFTs in the 
subjects with no or sparse amyloid pathology (CERAD NP density score = 0 or 1) and the 
relationship remained significant (Table 4).
DISCUSSION
In this large autopsy sample, we found that HC was associated with increased severity of 
neuropathology including NFTs, NP and DP densities, and CAA. These associations were 
independent of neuropathological CVD severity score and cannot be completely explained 
by ApoE ε4 carrier status.
Our findings were in general consistent with the Honolulu-Asia Aging Study (N = 218) [26], 
which reported a strong linear association for increasing midlife and late-life HDL 
cholesterol and an increasing number of neocortical NPs and NFTs. Another retrospective 
study (N = 140) [27] suggested that serum hypercholesterolemia was associated with AD 
amyloid pathology in subjects 40–55 years of age. This study only investigated amyloid 
pathology. The Hisayama Study [17] suggested that dyslipidemia increased the risk of 
plaque-type AD pathology but found no relationship between any lipid profile and NFTs. 
The absence of association between the lipid profiles and NFTs might be due to limited 
sample size (N = 147). Compared to previous studies, our study has the advantage of large 
sample size (N = 3508). We investigated a broader range of AD pathology indices, including 
NPs, DPs, NFTs, and CAA. Instead of measuring cholesterol level at a certain time point, 
we collected history of HC as an indicator of the potential risk. We believed that lifetime 
history would be a more stable and reliable measure compared to a single-time-point 
measurement. This study discovered that hypercholesterolemia was associated with 
increased risk of both amyloid and tau pathology, which is consistent with the majority of 
the animal and in vitro studies [10, 11].
An important innovation of our study was comparison of models with and without CVD 
scores. Based on these models we are able to conclude that CVD is not a mediator in the 
association of HC with AD pathology. Concurrent CVD is a common neuropathological 
finding in AD patients and is believed to contribute to AD neuropathological changes [28]. 
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Therefore, vascular risk factors, such as HC, might have increased the risk of AD through 
vascular mechanism [29]. Our study demonstrated that HC is associated with AD 
neuropathological changes independent of CVD burden.
Observational studies have shown conflicting results on the effect of statin use on AD [30]. 
In 2012, the United States Food and Drug Administration issued a warning of statin drugs 
labeling regarding potential adverse effects on cognition [31]. Randomized controlled trials 
that assessed the effects of statin use on cognition did not support a causal preventative 
effect [30] or adverse effect [32]. In our study, we found that the use of lipid lowering 
medications did not change the association between HC and AD neuropathology.
Since ApoE ε4 plays a crucial role in cholesterol metabolism and transport in the brain, and 
is also a strong genetic risk factor for AD pathogenesis, we examined the relationship 
between ApoE ε4 genotype, HC, and AD pathology by comparing two multivariate models 
(Model 2 and Model 3). The associations between HC and DP pathology or CAA were no 
longer significant after adjustment for ApoE ε4 genotype, yet the association with NP 
burden remained significant suggesting that ApoE ε4 genotype mediates the relationship of 
HC with vascular amyloid and early diffuse amyloid pathology but not so much the 
relationship with the mature plaques. Other genetic risk factors for AD, such as HMGR 
gene, which encodes the primary regulator of cholesterol synthesis, might be the additional 
linkage between abnormal cholesterol level and AD pathogenesis [33].
Extensive evidence supports that ApoE affects the risk of AD mainly through Aβ cascade 
[34, 35]. It was reported that ApoE genotype was only associated with tau pathology in the 
presence of Aβ, which was evaluated by immunohistochemistry [5]. Interestingly, we found 
a significant ApoE ε4 association with higher NFT burden even in subjects with no or sparse 
amyloid pathology (CERAD NP score = 0 or 1) (Table 4). The discrepancy between our 
results and the previous report may reflect the difference in methods for staging Aβ 
pathology. Although both methods quantify Aβ pathology, there is no consistent relationship 
between CERAD score system and immunohistochemical staining of Aβ, such as Thal Aβ 
phase [36]. In addition, the study by Farfel et al. included smaller number of subjects 
without Aβ compared to our current study (N = 152 compared to N = 1225) [5] and perhaps 
limited power to identify an association between ApoE ε4 genotype and tangles in 
subgroups stratified by Aβ. Based on our findings in Models 2 and 3, we conclude that the 
association between HC and NFTs is to a significant extent mediated by ApoE ε4 genotype.
Our study also had several limitations. First, the semiquantitative assessment of NPs and 
NFTs could affect the accuracy of the results. Second, we used self or caregiver reported 
medical history for hypercholesterolemia in our analysis, which may be subject to recall 
bias. Medication use was also collected from self or caregiver report and we did not consider 
duration or adherence of medication use. In addition, cholesterol levels were not available in 
this data set.
In conclusion, our study found that history of hypercholesterolemia, independent of its 
impact on cerebrovascular conditions, is associated with increased severity of AD pathology. 
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In addition to the well-established ApoE ε4 effect on Aβ pathology, this study found that 
ApoE ε4 is associated with increased NFT pathology in the absence of Aβ pathology.
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